బ్రెస్ట్ క్యాన్సర్

The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety profile by eliminating excipients, polysorbate 80 and ethanol which are present in conventional Docetaxel formulations (Taxotere®). This randomized, open-label study is designed to assess the efficacy and safety of Nanosomal Docetaxel Lipid Suspension at the dose of 75 mg/m2 and at the dose of 100 mg/m2 compared to Taxotere® at the dose of 100 mg/m2 in triple-…

స్పాన్సర్: జిన్నా ఫార్మాస్యూటికల్స్ ఇంక్.
NCT03671044 ఆన్ ClinicalTrials.gov
లాస్ట్ అప్డేటెడ్ ఆన్ ద రిజిస్ట్రీ 21 Mar 2025 · రీడ్ బై అస్ 20 Oct 2026